14 / 32
PFS AND OS, ENTRECTINIB
Data cut-off date: May 31 2018, ROS1-inihibitor-naïve patients with
ROS1+
NSCLC (integrated analysis population)
100
0
80
60
40
20
0
6
12
18
24
30
36
Time (months)
28
37
8
6
3
53
15
32
6
5
1
43
1
Total
Censored
Median + 95% CI
Total (N=53): 19.0 (12.2–36.6)
Median PFS 19.0 months
(95% CI 12.2, 36.6)
42
Total
No. at risk
PFS by BICR (%)
PFS,
ROS1+
NSCLC
12-month event-free
probability: 0.65